{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:18:29Z","timestamp":1793726309297,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40256-025-00771-8","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:09:26Z","timestamp":1761664166000},"page":"165-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations"],"prefix":"10.1007","volume":"26","author":[{"family":"Maryam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Treesa P.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tazneem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"17","key":"771_CR1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvac013.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"771_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40256-025-00735-y","volume":"25","author":"Maryam","year":"2025","unstructured":"Maryam, Varghese TP, Tazneem B, et al. Emerging role of weight-loss medications in the management of heart failure: current evidence and future perspectives. Am J Cardiovasc Drugs. 2025;25(5):593\u2013600. https:\/\/doi.org\/10.1007\/s40256-025-00735-y.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"771_CR3","doi-asserted-by":"publisher","first-page":"102411","DOI":"10.1016\/j.cpcardiol.2024.102411","volume":"49","author":"Maryam","year":"2024","unstructured":"Maryam, Varghese TP, Tazneem B. Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). Curr Probl Cardiol. 2024;49(4):102411. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102411.","journal-title":"Curr Probl Cardiol"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"28901","DOI":"10.1038\/s41598-024-78556-3","volume":"14","author":"M Abdullah","year":"2024","unstructured":"Abdullah M, Abdo B, Ahmed F, et al. Prevalence and independent predictors of iron deficiency in Yemeni patients with congestive heart failure: a retrospective cross-sectional study. Sci Rep. 2024;14:28901. https:\/\/doi.org\/10.1038\/s41598-024-78556-3.","journal-title":"Sci Rep"},{"key":"771_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.709872","volume":"8","author":"C Rizzo","year":"2021","unstructured":"Rizzo C, Carbonara R, Ruggieri R, et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;8:709872. https:\/\/doi.org\/10.3389\/fcvm.2021.709872.","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl 3","key":"771_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00508-025-02521-x","volume":"137","author":"M Messner","year":"2025","unstructured":"Messner M, P\u00f6lzl G, Adlbrecht C, et al. Diagnosis and treatment of iron deficiency in chronic heart failure\u202f: Position statement of the heart failure working group of the Austrian Society of Cardiology. Wien Klin Wochenschr. 2025;137(Suppl 3):143\u201356. https:\/\/doi.org\/10.1007\/s00508-025-02521-x.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"771_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/CIRCRESAHA.122.321667","volume":"132","author":"KT Sawicki","year":"2023","unstructured":"Sawicki KT, De Jesus A, Ardehali H. Iron metabolism in cardiovascular disease: physiology, mechanisms, and therapeutic targets. Circ Res. 2023;132(3):379\u201396. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321667.","journal-title":"Circ Res"},{"issue":"14","key":"771_CR8","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/nu14142976","volume":"14","author":"SB Kumar","year":"2022","unstructured":"Kumar SB, Arnipalli SR, Mehta P, et al. Iron deficiency anemia: efficacy and limitations of nutritional and comprehensive mitigation strategies. Nutrients. 2022;14(14):2976. https:\/\/doi.org\/10.3390\/nu14142976.","journal-title":"Nutrients"},{"key":"771_CR9","doi-asserted-by":"crossref","unstructured":"Arocha Rodulfo JI, Navas Blanco T, Amair MP, et al. Clinical implications of iron deficiency in heart failure, an approach to the treatment. Rev Colomb Nefrol. 2016;3(1):26\u201340. https:\/\/revistanefrologia.org\/index.php\/rcn\/article\/view\/238.","DOI":"10.22265\/acnef.3.1.238"},{"issue":"Suppl M","key":"771_CR10","doi-asserted-by":"publisher","first-page":"M32","DOI":"10.1093\/eurheartj\/suz231","volume":"21","author":"EA Jankowska","year":"2019","unstructured":"Jankowska EA, Tkaczyszyn M, Drozd M, et al. Monitoring of iron status in patients with heart failure. Eur Heart J Suppl. 2019;21(Suppl M):M32\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/suz231.","journal-title":"Eur Heart J Suppl"},{"issue":"34","key":"771_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000044060","volume":"104","author":"QH Doan","year":"2025","unstructured":"Doan QH, Tran AV, Dinh PTH, et al. Enhancing quality of life and functional capacity in heart failure patients with iron deficiency: a regional cross-sectional study on intravenous iron therapy in Vietnam. Medicine. 2025;104(34):e44060. https:\/\/doi.org\/10.1097\/MD.0000000000044060.","journal-title":"Medicine"},{"issue":"3","key":"771_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.236","volume":"17","author":"T McDonagh","year":"2015","unstructured":"McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail. 2015;17(3):248\u201362. https:\/\/doi.org\/10.1002\/ejhf.236.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"771_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092934","volume":"14","author":"L Anghel","year":"2025","unstructured":"Anghel L, Dinu C, Patra\u0219 D, et al. Iron deficiency treatment in heart failure-challenges and therapeutic solutions. J Clin Med. 2025;14(9):2934. https:\/\/doi.org\/10.3390\/jcm14092934.","journal-title":"J Clin Med"},{"issue":"12","key":"771_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.tem.2024.04.015","volume":"35","author":"MR Teh","year":"2024","unstructured":"Teh MR, Armitage AE, Drakesmith H. Why cells need iron: a compendium of iron utilisation. Trends Endocrinol Metab. 2024;35(12):1026\u201349. https:\/\/doi.org\/10.1016\/j.tem.2024.04.015.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"771_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/life12081203","volume":"12","author":"B Koz\u0142owska","year":"2022","unstructured":"Koz\u0142owska B, Sochanowicz B, Kraj L, et al. Clinical and molecular aspects of iron metabolism in failing myocytes. Life. 2022;12(8):1203. https:\/\/doi.org\/10.3390\/life12081203.","journal-title":"Life"},{"issue":"17","key":"771_CR16","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1089\/ars.2014.6123","volume":"22","author":"MA Aon","year":"2015","unstructured":"Aon MA, Tocchetti CG, Bhatt N, et al. Protective mechanisms of mitochondria and heart function in diabetes. Antioxid Redox Signal. 2015;22(17):1563\u201386. https:\/\/doi.org\/10.1089\/ars.2014.6123.","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"771_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ejhf.1154","volume":"20","author":"MF Hoes","year":"2018","unstructured":"Hoes MF, Grote Beverborg N, Kijlstra JD, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018;20(5):910\u20139. https:\/\/doi.org\/10.1002\/ejhf.1154.","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"771_CR18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1177\/2047487320906919","volume":"27","author":"L Angius","year":"2020","unstructured":"Angius L, Crisafulli A. Exercise intolerance and fatigue in chronic heart failure: is there a role for group III\/IV afferent feedback? Eur J Prev Cardiol. 2020;27(17):1862\u201372. https:\/\/doi.org\/10.1177\/2047487320906919.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"771_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","volume":"34","author":"EA Jankowska","year":"2013","unstructured":"Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816\u201329. https:\/\/doi.org\/10.1093\/eurheartj\/ehs224.","journal-title":"Eur Heart J"},{"issue":"1","key":"771_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010125","volume":"11","author":"RIS Alnuwaysir","year":"2021","unstructured":"Alnuwaysir RIS, Hoes MF, van Veldhuisen DJ, et al. Iron deficiency in heart failure: mechanisms and pathophysiology. J Clin Med. 2021;11(1):125. https:\/\/doi.org\/10.3390\/jcm11010125.","journal-title":"J Clin Med"},{"issue":"9","key":"771_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI20945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271\u20136. https:\/\/doi.org\/10.1172\/JCI20945.","journal-title":"J Clin Invest"},{"issue":"3","key":"771_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/MOH.0000000000000236","volume":"23","author":"CY Wang","year":"2016","unstructured":"Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol. 2016;23(3):189\u201397. https:\/\/doi.org\/10.1097\/MOH.0000000000000236.","journal-title":"Curr Opin Hematol"},{"key":"771_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2025.109888","volume":"140","author":"A Catapano","year":"2025","unstructured":"Catapano A, Cimmino F, Petrella L, et al. Iron metabolism and ferroptosis in health and diseases: the crucial role of mitochondria in metabolically active tissues. J Nutr Biochem. 2025;140:109888. https:\/\/doi.org\/10.1016\/j.jnutbio.2025.109888.","journal-title":"J Nutr Biochem"},{"issue":"3","key":"771_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030329","volume":"16","author":"N Scaramellini","year":"2023","unstructured":"Scaramellini N, Fischer D, Agarvas AR, et al. Interpreting iron homeostasis in congenital and acquired disorders. Pharmaceuticals (Basel). 2023;16(3):329. https:\/\/doi.org\/10.3390\/ph16030329.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"771_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2169\/internalmedicine.9554-17","volume":"57","author":"R Imai","year":"2018","unstructured":"Imai R, Higuchi T, Morimoto M, et al. Iron deficiency anemia due to the long-term use of a proton pump inhibitor. Intern Med. 2018;57(6):899\u2013901. https:\/\/doi.org\/10.2169\/internalmedicine.9554-17.","journal-title":"Intern Med"},{"issue":"6","key":"771_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/ejhf.3237","volume":"26","author":"M Packer","year":"2024","unstructured":"Packer M, Anker SD, Butler J, et al. Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. Eur J Heart Fail. 2024;26(6):1298\u2013312. https:\/\/doi.org\/10.1002\/ejhf.3237.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"771_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13020304","volume":"13","author":"CE Singer","year":"2023","unstructured":"Singer CE, Vasile CM, Popescu M, et al. Role of iron deficiency in heart failure-clinical and treatment approach: an overview. Diagnostics. 2023;13(2):304. https:\/\/doi.org\/10.3390\/diagnostics13020304.","journal-title":"Diagnostics"},{"key":"771_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5124553","volume":"2022","author":"F Yan","year":"2022","unstructured":"Yan F, Li K, Xing W, et al. Role of iron-related oxidative stress and mitochondrial dysfunction in cardiovascular diseases. Oxid Med Cell Longev. 2022;2022:5124553. https:\/\/doi.org\/10.1155\/2022\/5124553.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"771_CR29","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.bbadis.2018.08.030","volume":"1865","author":"H Zhang","year":"2019","unstructured":"Zhang H, Zhabyeyev P, Wang S, et al. Role of iron metabolism in heart failure: from iron deficiency to iron overload. Biochimica et Biophysica Acta (BBA). 2019;1865(7):1925\u201337. https:\/\/doi.org\/10.1016\/j.bbadis.2018.08.030.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"42","key":"771_CR30","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1093\/eurheartj\/ehae359","volume":"45","author":"M Vera-Aviles","year":"2024","unstructured":"Vera-Aviles M, Kabir SN, Shah A, et al. Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway. Eur Heart J. 2024;45(42):4497\u2013508. https:\/\/doi.org\/10.1093\/eurheartj\/ehae359.","journal-title":"Eur Heart J"},{"issue":"2","key":"771_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","volume":"150","author":"M Packer","year":"2024","unstructured":"Packer M, Anker SD, Butler J, et al. Redefining iron deficiency in patients with chronic heart failure. Circulation. 2024;150(2):151\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.068883.","journal-title":"Circulation"},{"issue":"37","key":"771_CR32","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, ESC Scientific Document Group, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"9","key":"771_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/HCQ.0000000000000132","volume":"17","author":"MM Kittleson","year":"2024","unstructured":"Kittleson MM, Breathett K, Ziaeian B, et al. 2024 update to the 2020 ACC\/AHA clinical performance and quality measures for adults with heart failure: a report of the American Heart Association\/American College of Cardiology joint committee on performance measures. Circ Cardiovasc Qual Outcomes. 2024;17(9):e000132. https:\/\/doi.org\/10.1161\/HCQ.0000000000000132.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25","key":"771_CR34","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, FAIR-HF Trial Investigators, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348. https:\/\/doi.org\/10.1056\/NEJMoa0908355.","journal-title":"N Engl J Med"},{"issue":"11","key":"771_CR35","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, CONFIRM-HF Investigators, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385.","journal-title":"Eur Heart J"},{"issue":"10266","key":"771_CR36","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4.","journal-title":"Lancet"},{"issue":"19","key":"771_CR37","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, NHLBI Heart Failure Clinical Research Network, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958\u201366. https:\/\/doi.org\/10.1001\/jama.2017.5427.","journal-title":"JAMA"},{"issue":"37","key":"771_CR38","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling S, Doehner W, Evertz R, et al. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J. 2024;45(37):3789\u2013800. https:\/\/doi.org\/10.1093\/eurheartj\/ehae479.","journal-title":"Eur Heart J"},{"issue":"7","key":"771_CR39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11886-023-01889-4","volume":"25","author":"A Shamsi","year":"2023","unstructured":"Shamsi A, Cannata A, Piper S, et al. Treatment of iron deficiency in heart failure. Curr Cardiol Rep. 2023;25(7):649\u201361. https:\/\/doi.org\/10.1007\/s11886-023-01889-4.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"771_CR40","doi-asserted-by":"publisher","DOI":"10.31083\/RCM28216","volume":"26","author":"HP Sung","year":"2025","unstructured":"Sung HP, Yin WH, Chen SF, et al. Intravenous iron sucrose for acute decompensated heart failure patients with reduced ejection fraction and iron deficiency. Rev Cardiovasc Med. 2025;26(4):28216. https:\/\/doi.org\/10.31083\/RCM28216.","journal-title":"Rev Cardiovasc Med"},{"issue":"10369","key":"771_CR41","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, IRONMAN Study Group, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199\u2013209. https:\/\/doi.org\/10.1016\/S0140-6736(22)02083-9.","journal-title":"Lancet"},{"issue":"2","key":"771_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001704","volume":"8","author":"A Abboud","year":"2021","unstructured":"Abboud A, Nguonly A, Bean A, et al. Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart. 2021;8(2):e001704. https:\/\/doi.org\/10.1136\/openhrt-2021-001704.","journal-title":"Open Heart"},{"issue":"6","key":"771_CR43","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/ehf2.12503","volume":"6","author":"P Martens","year":"2019","unstructured":"Martens P, Dupont M, Dauw J, Somers F, et al. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy. ESC Heart Fail. 2019;6(6):1208\u201315. https:\/\/doi.org\/10.1002\/ehf2.12503.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"771_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001012","volume":"6","author":"AL Beale","year":"2019","unstructured":"Beale AL, Warren JL, Roberts N, et al. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1):e001012. https:\/\/doi.org\/10.1136\/openhrt-2019-001012.","journal-title":"Open Heart"},{"issue":"2","key":"771_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14020209","volume":"14","author":"FD K\u00f6seo\u011flu","year":"2024","unstructured":"K\u00f6seo\u011flu FD, \u00d6zlek B. Anemia and iron deficiency predict all-cause mortality in patients with heart failure and preserved ejection fraction: 6-year follow-up study. Diagnostics (Basel). 2024;14(2):209. https:\/\/doi.org\/10.3390\/diagnostics14020209.","journal-title":"Diagnostics (Basel)"},{"issue":"13","key":"771_CR46","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1111\/bph.15065","volume":"177","author":"F Savira","year":"2020","unstructured":"Savira F, Magaye R, Liew D, et al. Cardiorenal syndrome: multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol. 2020;177(13):2906\u201322. https:\/\/doi.org\/10.1111\/bph.15065.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"771_CR47","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.3324\/haematol.2024.284967","volume":"109","author":"K Pantopoulos","year":"2024","unstructured":"Pantopoulos K. Oral iron supplementation: new formulations, old questions. Haematologica. 2024;109(9):2790\u2013801. https:\/\/doi.org\/10.3324\/haematol.2024.284967.","journal-title":"Haematologica"},{"issue":"5","key":"771_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13050746","volume":"13","author":"CY Lin","year":"2023","unstructured":"Lin CY, Sung HY, Chen YJ, et al. Personalized management for heart failure with preserved ejection fraction. J Pers Med. 2023;13(5):746. https:\/\/doi.org\/10.3390\/jpm13050746.","journal-title":"J Pers Med"},{"issue":"3","key":"771_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.19268","volume":"204","author":"PO Ebea-Ugwuanyi","year":"2024","unstructured":"Ebea-Ugwuanyi PO, Vidyasagar S, Connor JR, et al. Oral iron therapy: current concepts and future prospects for improving efficacy and outcomes. Br J Haematol. 2024;204(3):759\u201373. https:\/\/doi.org\/10.1111\/bjh.19268.","journal-title":"Br J Haematol"},{"issue":"4","key":"771_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040127","volume":"11","author":"A Katsarou","year":"2018","unstructured":"Katsarou A, Pantopoulos K. Hepcidin therapeutics. Pharmaceuticals (Basel). 2018;11(4):127. https:\/\/doi.org\/10.3390\/ph11040127.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"771_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011728","volume":"18","author":"S Gan","year":"2025","unstructured":"Gan S, Azzo JD, Zhao L, et al. Transferrin saturation, serum iron, and ferritin in heart failure: prognostic significance and proteomic associations. Circ Heart Fail. 2025;18(2):e011728. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.011728.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"771_CR52","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/HCG.0000000000000058","volume":"12","author":"S Cresci","year":"2019","unstructured":"Cresci S, Pereira NL, Ahmad F, et al. Heart failure in the era of precision medicine: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2019;12(10):458\u201385. https:\/\/doi.org\/10.1161\/HCG.0000000000000058.","journal-title":"Circ Genom Precis Med"},{"issue":"2","key":"771_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jjcc.2023.06.012","volume":"83","author":"K Bhatia","year":"2024","unstructured":"Bhatia K, Sabharwal B, Gupta K, et al. Clinical outcomes of intravenous iron therapy in patients with heart failure and iron deficiency: meta-analysis and trial sequential analysis of randomized clinical trials. J Cardiol. 2024;83(2):105\u201312. https:\/\/doi.org\/10.1016\/j.jjcc.2023.06.012.","journal-title":"J Cardiol"},{"key":"771_CR54","doi-asserted-by":"publisher","first-page":"1326144","DOI":"10.3389\/fmed.2024.1326144","volume":"11","author":"O Tomobi","year":"2024","unstructured":"Tomobi O, Avoian S, Ekwere I, et al. A comparative analysis of intravenous infusion methods for low-resource environments. Front Med. 2024;11:1326144. https:\/\/doi.org\/10.3389\/fmed.2024.1326144.","journal-title":"Front Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00771-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:23:56Z","timestamp":1771507436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00771-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Maryam conceptualized the study and drafted the initial and the revised manuscript . Dr. Treesa P. Varghese reviewed the final manuscript for accuracy. Dr. Tazneem contributed to the literature review. All the authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}